Verition Fund Management LLC Buys Shares of 44,355 X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

Verition Fund Management LLC purchased a new position in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 44,355 shares of the company’s stock, valued at approximately $30,000.

Other institutional investors have also recently made changes to their positions in the company. GSA Capital Partners LLP bought a new position in X4 Pharmaceuticals in the third quarter worth approximately $340,000. K2 Principal Fund L.P. purchased a new position in shares of X4 Pharmaceuticals in the 2nd quarter valued at $284,000. AQR Capital Management LLC increased its holdings in shares of X4 Pharmaceuticals by 1,080.3% in the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after acquiring an additional 388,115 shares during the period. Bank of New York Mellon Corp raised its position in shares of X4 Pharmaceuticals by 39.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock worth $272,000 after acquiring an additional 133,398 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth $65,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Stock Up 14.5 %

Shares of XFOR stock opened at $0.74 on Wednesday. The stock’s fifty day moving average price is $0.49 and its 200 day moving average price is $0.66. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. X4 Pharmaceuticals, Inc. has a 1-year low of $0.26 and a 1-year high of $1.60. The company has a market cap of $125.98 million, a price-to-earnings ratio of -8.21 and a beta of 0.35.

Insider Activity

In other X4 Pharmaceuticals news, COO Mary Dibiase sold 67,695 shares of X4 Pharmaceuticals stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.57, for a total transaction of $38,586.15. Following the completion of the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at approximately $257,674.20. The trade was a 13.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Adam S. Mostafa sold 230,645 shares of X4 Pharmaceuticals stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $126,854.75. The disclosure for this sale can be found here. Insiders have sold a total of 580,800 shares of company stock worth $321,447 over the last 90 days. 1.62% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on XFOR shares. HC Wainwright cut their target price on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Stifel Nicolaus cut their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.